A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis

Background  Data from an uncontrolled trial suggest synchronous balneophototherapy (sBPT), which simulates treatment conditions at the Dead Sea, to be effective in the management of atopic dermatitis (AD). Objectives  The purpose of this prospective randomized controlled study was to compare the eff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the European Academy of Dermatology and Venereology 2011-07, Vol.25 (7), p.765-773
Hauptverfasser: Heinlin, J., Schiffner-Rohe, J., Schiffner, R., Einsele-Krämer, B., Landthaler, M., Klein, A., Zeman, F., Stolz, W., Karrer, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background  Data from an uncontrolled trial suggest synchronous balneophototherapy (sBPT), which simulates treatment conditions at the Dead Sea, to be effective in the management of atopic dermatitis (AD). Objectives  The purpose of this prospective randomized controlled study was to compare the efficacy and safety of sBPT with narrow‐band (NB) UVB monotherapy (PT) for AD. Methods  In this phase III multicentre trial, 180 patients with moderate‐to‐severe AD were allocated to two groups in a 1 : 1 ratio; group 1 received sBPT consisting of NB UVB treatment and synchronous bathing in 10% Dead Sea salt solution, group 2 monotherapy with UVB 311 nm. The confirmatory study design consisted of up to 35 treatment sessions. Primary endpoint, analysed on an intention‐to‐treat‐basis (n = 169), was the relative improvement of the severity SCORing of the Atopic Dermatitis Index (SCORAD) from baseline to the end of treatment (35 sessions or early cure). Sample‐size calculation aimed at establishing at least 15% superiority. Results  SCORing of the Atopic Dermatitis Index at baseline was comparable between sBPT (61.8 ± 14.1) and PT (61.5 ± 12.4) group. At the end of therapy, a clinically relevant and statistically significant difference of 26.2% could be shown (P 
ISSN:0926-9959
1468-3083
DOI:10.1111/j.1468-3083.2010.03857.x